Impact of vitamin D receptor gene polymorphisms on vitiligo susceptibility and clinical features in a Southeastern European Caucasian population.
Adolescent
Adult
Aged
Case-Control Studies
Europe
Female
Gene Frequency
/ genetics
Genetic Association Studies
Genetic Predisposition to Disease
Humans
Male
Middle Aged
Phenotype
Polymorphism, Genetic
Polymorphism, Single Nucleotide
/ genetics
Receptors, Calcitriol
/ genetics
Vitiligo
/ genetics
White People
/ genetics
Young Adult
Journal
International journal of molecular medicine
ISSN: 1791-244X
Titre abrégé: Int J Mol Med
Pays: Greece
ID NLM: 9810955
Informations de publication
Date de publication:
Nov 2020
Nov 2020
Historique:
received:
17
08
2020
accepted:
18
09
2020
pubmed:
2
10
2020
medline:
3
7
2021
entrez:
1
10
2020
Statut:
ppublish
Résumé
An association of vitamin D receptor (VDR) polymorphisms and vitiligo has been suggested. However, previous studies have reported contradictory results while including limited data among Caucasians. The aim of this single‑center study was to evaluate the effect of three common VDR gene polymorphisms (FokI, TaqI and BsmI) on susceptibility and clinical aspects of vitiligo in a Southeastern European Caucasian population. A total of 110 unrelated vitiligo cases and 509 general population controls were enrolled from October 2018 to November 2019. Genomic DNA was extracted from whole blood after de‑identification and anonymization of the samples and genotyped for the selected VDR polymorphisms by the qPCR (melting curve analysis). Subgroup analysis by clinical features among subsets of patients indicated that, compared to subjects with the FokI TT genotype or T allele, carriers of the FokI CC genotype or C allele exhibited significantly decreased risk of developing vitiligo before the age of 30 [TT vs. CC: odds ratio (OR)=0.286, 95% confidence interval (CI): 0.083‑0.984, P=0.041; T vs. C: OR=0.545, 95% CI: 0.313‑0.948, P=0.031]. Intra‑patient analysis also revealed that, compared to T allele, the presence of TaqI C allele was adversely associated with the incidence of concurrent leukotrichia (T vs. C: OR=1.874, 95% CI: 1.018‑3.451, P=0.042). Comparisons between the case and control groups showed no evidence to support an association between susceptibility to vitiligo and the VDR BsmI, TaqI, and FokI polymorphisms in this cohort. Thus, the studied VDR polymorphisms might indirectly impact the clinical course and treatment decision‑making despite their lack of association with vitiligo per se. Further research with larger sample sizes, especially across Caucasian individuals, should be performed to confirm these findings.
Identifiants
pubmed: 33000207
doi: 10.3892/ijmm.2020.4732
pmc: PMC7521563
doi:
Substances chimiques
Receptors, Calcitriol
0
VDR protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1899-1907Références
Gene. 2004 Sep 1;338(2):143-56
pubmed: 15315818
Gene. 2015 May 1;561(2):171-80
pubmed: 25682935
Photodermatol Photoimmunol Photomed. 2016 Jul;32(4):181-90
pubmed: 27005676
Pigment Cell Melanoma Res. 2009 Aug;22(4):487-8
pubmed: 19422605
Autoimmun Rev. 2019 Sep;18(9):102350
pubmed: 31323357
Br J Dermatol. 2013 Apr;168(4):855-8
pubmed: 23034014
Dermatol Clin. 2017 Apr;35(2):245-255
pubmed: 28317533
Mol Med Rep. 2013 Jan;7(1):237-41
pubmed: 23042234
Am J Clin Dermatol. 2018 Apr;19(2):223-235
pubmed: 28994020
Br J Dermatol. 2012 Oct;167(4):815-21
pubmed: 22762534
Med Res Rev. 2009 May;29(3):514-46
pubmed: 19241402
Pigment Cell Melanoma Res. 2020 Jan;33(1):8-15
pubmed: 31743585
Oncol Rep. 2019 Dec;42(6):2228-2244
pubmed: 31578582
Acta Derm Venereol. 2006;86(3):209-14
pubmed: 16710576
Exp Ther Med. 2013 Oct;6(4):967-972
pubmed: 24137299
Front Genet. 2018 Nov 28;9:560
pubmed: 30546380
Clin Exp Dermatol. 2019 Jul;44(5):498-505
pubmed: 30474246
J Mol Neurosci. 2020 Jun;70(6):851-860
pubmed: 32088842
Int J Dermatol. 2019 Nov;58(11):1264-1269
pubmed: 31120146
Mol Med Rep. 2017 Nov;16(5):6059-6067
pubmed: 28849089
Hum Mol Genet. 2004 Aug 1;13(15):1633-9
pubmed: 15175274
Dermatology. 2012;224(4):361-8
pubmed: 22738935
J Mol Neurosci. 2018 Jul;65(3):367-376
pubmed: 29959630
Indian Dermatol Online J. 2019 Mar-Apr;10(2):131-138
pubmed: 30984586
Exp Dermatol. 2014 Apr;23(4):219-23
pubmed: 24521008
Mol Med Rep. 2016 Jul;14(1):630-6
pubmed: 27221532
Pigment Cell Melanoma Res. 2012 May;25(3):E1-13
pubmed: 22417114
J Eur Acad Dermatol Venereol. 2019 Sep;33(9):1667-1675
pubmed: 31131483
Toxicology. 2019 Jan 1;411:24-31
pubmed: 30359673
Int J Dermatol. 2011 Aug;50(8):925-7
pubmed: 21781062
Lancet. 2015 Jul 4;386(9988):74-84
pubmed: 25596811
Medicine (Baltimore). 2018 Jul;97(29):e11506
pubmed: 30024533
Int J Dermatol. 2016 Dec;55(12):1329-1335
pubmed: 27420410
Clin Exp Dermatol. 2015 Oct;40(7):794-803
pubmed: 25788285